Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 (PD-1 antibody) in advanced or metastatic solid tumors
CTR20191370Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Sep 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in Nonhematologic neoplasms, sponsored by Akeso, Inc.. Started Sep 2019; status: completed.
02
Drugs
penpulimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20191370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191370.